Published – positive findings from the Phase 2b study with NT-814, a novel non-hormonal treatment for symptoms of the menopause

KaNDy Therapeutics’ SWITCH-1 abstract, accepted for presentation at the 2020 ENDO Conference, has now been published in the Journal of Endocrine Society. The data were due to have been presented by Dr James Simon (George Washington University) but the meeting was cancelled due to COVID-19. The published abstract discusses the positive findings from the Phase 2b study (named SWITCH-1) with NT-814, a unique non-hormonal dual NK 1,3 receptor antagonist. In the SWITCH-1 study, the frequency of hot flashes was significantly reduced by NT-814 throughout the 12 weeks of treatment. These benefits were accompanied by significant improvements in quality of life, mood and sleep. You can read the full abstract here: